Filamentous Bacteriophage—A Powerful Carrier for Glioma Therapy

作者：Yicun Wang, Jiyao Sheng, Jin Chai, Cuilin Zhu, Xin Li, Wei Yang, Ranji Cui, Tongtong Ge · 发表于：Frontiers in Immunology · 年份：2021 · DOI：10.3389/fimmu.2021.729336 · 被引用次数：20 · 研究领域：Monoclonal and Polyclonal Antibodies Research、Bacteriophages and microbial interactions、Glycosylation and Glycoproteins Research

Glioma is a life-threatening malignant tumor. Resistance to traditional treatments and tumor recurrence present major challenges in treating and managing this disease, consequently, new therapeutic strategies must be developed. Crossing the blood-brain barrier (BBB) is another challenge for most drug vectors and therapy medications. Filamentous bacteriophage can enter the brain across the BBB. Compared to traditional drug vectors, phage-based drugs offer thermodynamic stability, biocompatibility, homogeneity, high carrying capacity, self-assembly, scalability, and low toxicity. Tumor-targeting peptides from phage library and phages displaying targeting peptides are ideal drug delivery agents. This review summarized recent studies on phage-based glioma therapy and shed light on the developing therapeutics phage in the personalized treatment of glioma.